83
Participants
Start Date
January 4, 2012
Primary Completion Date
July 15, 2013
Study Completion Date
July 15, 2013
SPD503 (extended-release Guanfacine hydrochloride)
Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
Placebo
Once-daily oral dosing in the evening for 12 weeks.
Columbia University, NY State Psychiatric Institute, New York
Weill Cornell Medical Center, New York
Richmond Behavioral Associates, Staten Island
Finger Lakes Clinical Research, Rochester
NeuroScience, Inc., Herndon
Coastal Carolina Research Center, Mt. Pleasant
Atlanta Center for Medical Research, Atlanta
Sarkis Clinical Trials, Gainesville
Kolin Research Group, Winter Park
Florida Clinical Research Center, Bradenton
Birmingham Research Group, Inc, Birmingham
Research Strategies of Memphis, LLC, Memphis
University Hospitals of Cleveland Medical Center, Cleveland
North Star Research, Middleburg Heights
Professional Psychiatric Services, Mason
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati
Rochester Center for Behavioral Medicine, Rochester Hills
Midwest Research Group, Saint Charles
Premier Psychiatric Group, LLC, Lincoln
Lake Charles Clinical Trials, Lake Charles
IPS Research Company, Oklahoma City
Houston Clinical Trials LLC, Houston
FutureSearch Clinical Trials, LP, Austin
Ericksen Research and Development, Clinton
Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas
Dr. Joseph H. Rodd, Carson
Sharp Mesa Vista Hospital, Clinical Research Department, San Diego
Sun Valley Research, Imperial
Elite Clinical Trials, Inc, Wildomar
Irvine Center for Clinical Research, Irvine
Institute of Behavioral Medicine, LLC, Smyrna
Center for Emotional Fitness, Cherry Hill
Duke University Medical Center, Duke Child and Family Study Center, Durham
Lead Sponsor
Shire
INDUSTRY